On Dec. 3, 2016, Celgene, Dana-Farber Cancer Institute and the University of Arkansas for Medical Sciences announced the creation of the Myeloma Genome Project, a collaborative initiative aimed at compiling the largest dataset of high-quality genomic and clinical data to identify distinct molecular disease segments within multiple myeloma to advance diagnosis, prognosis and treatment of multiple myeloma patients. The initiative sought to develop clinically relevant tests.

Current technologies discovered five major translocation groups within myeloma patients and these mutations have demonstrated varying effects on prognosis.